415 Capital is a specialist venture capital firm dedicated to investing in breakthrough and life-saving medical innovation. For over 30 years, our team has empowered exceptional entrepreneurs through the provision of capital, expertise, and market access.
We exclusively invest in large unmet patient needs in chronic diseases, with an emphasis on cardio & neurovascular disorders, the worldwide leading causes of death and the largest cost driver in the global healthcare systems. Our mission is to improve patient outcomes and quality of life at lower long-term healthcare costs.
Over the years, the 415 team has introduced over 25 breakthrough technologies to market and realized over 20 successful portfolio exits to-date, including Vesper Medical and Intact Vascular (both acquired by Philips), Claret Medical (acquired by Boston Scientific), ReCor Medical (acquired by Otsuka), CardiAQ Valve Technologies (acquired by Edwards), Atritech (acquired by Boston Scientific), CoreValve (acquired by Medtronic) and many more.
Company Details
- Employees
- 11
- Address
- Widenmayerstraße 15, Munich,bavaria 80538,germany
- Industry
- Venture Capital And Private Equity Principals
- NAICS
-
Miscellaneous Intermediation
- Website
- 415capital.com
- Keywords
- Hamburg.
- HQ
- Munich, Bavaria
415 Capital Questions
415 Capital's website is 415capital.com
415 Capital's LinkedIn profile is https://de.linkedin.com/company/415-capital
415 Capital has
11 employees.
View email and phone details for 11
employees at 415 Capital.
415 Capital's industry is
Venture Capital and Private Equity Principals
415 Capital's top competitors are
Sofinnova Partners,
Merieux Equity Partners,
Panakes Partners,
Reia Capital,
Corflow,
Unorthodox Ventures,
Hadean Ventures,
Laerdal Million Lives Fund,
Apollo Health Ventures,
Broadview Ventures Inc.
415 Capital's categories are Venture Capital and Private Equity Principals
